Skip to main navigation
  • About Us
    • Mission
    • Executive Officers
    • Board of Directors
    • In the Community
    • Contact Us
  • Our ADC Technology
    • What is an ADC?
    • ADC Design
    • With Checkpoint Inhibitors
    • Our Partners
    • Kadcyla
  • Pipeline
    • Mirvetuximab Soravtansine
    • Coltuximab Ravtansine
    • IMGN529
    • IMGN779
    • IMGN632
    • Cancer Trials
    • Partner Compounds
    • Publications
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Officers
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • Contact Us
  • Careers
    • Benefits
ImmunoGen, Inc.
  • About Us
    • Mission
    • Executive Officers
    • Board of Directors
    • In the Community
    • Contact Us
  • Our ADC Technology
    • What is an ADC?
    • ADC Design
    • With Checkpoint Inhibitors
    • Our Partners
    • Kadcyla
  • Pipeline
    • Mirvetuximab Soravtansine
    • Coltuximab Ravtansine
    • IMGN529
    • IMGN779
    • IMGN632
    • Cancer Trials
    • Partner Compounds
    • Publications
  • Investors

    Investor

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Contact Us
  • Careers
    • Benefits
  • Contact Us
  • 4

    SEC Filing Details

    Document Details

    Form
    4
    Filing Date
    Jan 3, 2018
    Document Date
    Dec 31, 2017
    Form Description
    Statement of changes in beneficial ownership of securities
    Filing Group
    3,4,5
    Company
    ImmunoGen, Inc.
    Issuer
    IMMUNOGEN INC
    Filer
    Goldberg Mark A

    Filing Formats

    View HTML
    Download PDF
    Download DOC

      Shareholder Tools

      • Email Alerts
      • Print
      • Share

      • Facebook
      • Google
      • LinkedIn
      • Twitter
      • RSS

    Investor Relations

    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Contact Us
    © 2018 ImmunoGen, Inc.. Sitemap | Privacy Policy | Usage Policy